Inflammatory bowel disease registry and monitoring: Feasibility study and application (Isfahan Inflammatory Bowel Disease Surveillance Project)

Abstract

Background:Inflammatory bowel disease (IBD) incidence has been increased in Iran as a developing country. Surveillance is a standard method for accessing valid data about disease epidemiology to make relevant decisions for disease control, prevention, and management. We designed Isfahan IBD Surveillance Project (IISP) to make a surveillance system in this area.Methods:The project is designed in 3 phases. At the first phase, a model of step-wise approach (core, expanded core, and optional variables) for IBD surveillance was designed and implemented among IBD patients registered at a major referral gastrointestinal diseases clinic in Isfahan. Data bank program and its software were designed with suitable and multifunctional features. A total of 352 IBD cases were registered to data bank and analyzed as a pilot study of IISP.Results:A total of 352 IBD patients, including 245 ulcerative colitis (UC), 80 Crohn's disease (CD), and 27 indeterminate colitis, were registered to the data bank. Bloody stool and abdominal cramp were the most common presentation symptom among UC and CD, respectively. Extensive pancolitis was the most prevalent phenotype (40%) of UC. Over two-thirds of our IBD patients were in remission states. Biologic agents had been prescribed in about 10% of patients during disease. Primary sclerosing cholangitis was detected in about 7% and 10% of CD and UC patients, respectively.Conclusions:Valid data from a standard surveillance system are a relevant, trustworthy tool for making decision by health policy-makers. Integrated comprehensive interventional programs for disease control and management is the second phase of IISP.

Effectiveness of treatment moderate ulcerative colitis with prolonged-release ethylcellulose-coated mesalazine in real clinical practice in Moscow

“…Выбор консервативного или хирургического лечения определяется тяжестью атаки, протяженностью поражения толстой кишки, наличием внекишечных проявлений, длительностью заболевания, эффективностью и безопасностью ранее проводившейся терапии, а также риском развития осложнений ЯК. Последние исследования свидетельствуют о том, что для обеспечения длительной стойкой ремиссии пациенты с ЯК должны оставаться на постоянной противорецидивной терапии [8,9]. Однако у половины больных ЯК рецидивирует в течение первого года после установления диагноза, ремиссия в течение 3-7 лет сохраняется лишь у ¼ больных, а ежегодные рецидивы наблюдаются у 1/5 из них.…”

Gastrointestinal and renal complications in SARS‐CoV‐2‐infected patients: Role of immune system

“…An important concern in SARS‐CoV‐2 pandemic is patients with immune‐mediated disease like IBD (inflammatory bowel diseases) and concurrent SARS‐CoV‐2 infection. It seemed that patients with IBD like Crohn's disease and ulcerative colitis are more susceptible to viral infections 149,150 . IBD as an inflammatory condition in the colon and small intestine is caused by an excessive immune response against luminal bacteria in the GI tract 151 .…”

Prevalence of intestinal protozoan infection in patients with ulcerative colitis (UC) in Isfahan, Iran

“…If corticosteroid has not been effective, surgical intervention must be carried out. [ 15 16 ] Patients with UC have an increased risk of colon cancer. The annual incidence of UC is between nine and 12 cases per 100,000 persons in the United States.…”